STOCK TITAN

Globus Medical (GMED) Stock News

GMED NYSE

Globus Medical reports recurring developments in musculoskeletal technology, including sales and earnings updates for its spine, orthopedic and enabling technology businesses. The company develops medical devices, instruments and computer-assisted systems used in musculoskeletal procedures and sells to hospitals, physicians and surgical centers in the United States and international markets.

Company news also covers US Spine demand, Enabling Technologies customer expansion, product pipeline execution, integration activity following completed NuVasive and Nevro transactions, preliminary sales guidance, earnings conference calls and board composition changes.

Rhea-AI Summary

Globus Medical (GMED) is scheduled to participate in the Jefferies Global Healthcare Conference in London on November 18, 2026.

Management is scheduled to present from 11:30–11:55 GMT. A live and archived webcast will be available through the Events & Webcasts section of the company’s investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
none
-
Rhea-AI Summary

Globus Medical (NYSE: GMED) reported third-quarter results and announced a $500 million increase to its existing share repurchase authorization. Quarterly sales fell 0.7% to $763.7 million, while GAAP net income rose 18.7% to $141.2 million and diluted earnings per share increased 18.2% to $1.04. Adjusted diluted earnings per share rose 4.4% to $1.23.

Base business sales, excluding Nevro, increased 3.0% to $690.0 million. U.S. sales grew 0.5%, but international sales declined 5.7%. GAAP gross margin reached 66.7%, versus 64.2% a year earlier. Globus lowered its 2026 revenue outlook to $3.09 billion from $3.18 billion–$3.22 billion, while reaffirming adjusted diluted earnings guidance of $4.95–$5.05 per share. The board approved the additional repurchase authorization on November 2, 2026; the program has no expiration date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.76%
Tags
buybacks earnings
-
Rhea-AI Summary

Globus Medical (GMED) completed its acquisition of Synaptive Medical on August 4, 2026, adding technologies for cranial neurosurgery to its portfolio. The transaction took place through a court-appointed receivership process. Synaptive's technologies span surgical visualization, navigation, surgical planning and MRI.

Globus Medical has begun outreach to customers and stakeholders and is establishing service and support for Synaptive's installed base while finalizing its long-term commercial strategy. The company identifies customer continuity as its immediate priority and sees opportunities to combine Synaptive's technologies with its Excelsius ecosystem to develop integrated procedural solutions. Synaptive also brings relationships with neurosurgical centers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.45%
Tags
Rhea-AI Summary

Globus Medical (GMED) will showcase its SCRIPT patient-specific spinal implant platform and new XLIF Prone Procedural Solution at NASS 2026. The meeting takes place in San Antonio, Texas, on October 14–17. SCRIPT is FDA-cleared and will receive an exclusive preview as the company moves toward commercialization.

SCRIPT Studio lets surgeons develop preoperative plans and implant designs, with plans transferable to ExcelsiusGPS or ExcelsiusHub for surgical navigation. The XLIF Prone Procedural Solution includes the XLIF Prone Patient Positioner and MaXcess Air two-blade retractor, designed to connect patient positioning and lateral surgical access.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.01%
Tags
none
-
Rhea-AI Summary

Globus Medical (NYSE:GMED) will release its third-quarter financial results after the market close on November 5, 2026.

The results cover the quarter ended September 30, 2026. A conference call will follow at 4:30 p.m. Eastern Time, with a live webcast and an audio archive afterward on the company's Investors website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.10%
Tags
conferences earnings date
-
Rhea-AI Summary

Globus Medical (GMED) announced that its Excelsius3D™ intelligent 3‑in‑1 imaging system has received CE marking for commercial sale in the European Union and the United Kingdom. The system expands the Excelsius™ Ecosystem and is designed to enhance the ExcelsiusGPS™ robotic navigation platform.

Excelsius3D™ combines 3D cone‑beam CT, 2D fluoroscopy, and digital radiography in a single mobile, intraoperative imaging platform. It can function as a stand‑alone system or be fully integrated with ExcelsiusGPS™, supporting a streamlined surgical workflow. The system previously received U.S. FDA 510(k) clearance in 2021, and Globus Medical will now begin commercialization in EU and UK markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
none
Rhea-AI Summary

Globus Medical (NYSE: GMED) announced the acquisition of Durham, NC-based Higgs Boson Health, a digital healthcare experience company incubated out of Duke University. Higgs Boson focuses on AI-driven software to enhance patient and provider experience across the full episode of care.

According to Globus Medical, Higgs Boson’s teams of software developers and AI scientists will join the company to support its vision of a seamless digital healthcare environment. The technology is intended to strengthen Globus Medical’s surgical intelligence pillar by integrating outcomes and analytics along the patient journey, with the stated long-term goal of improving musculoskeletal surgery outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
-
Rhea-AI Summary

Globus Medical (NYSE: GMED) reported second quarter 2026 worldwide net sales of $789.6 million, up 5.9% year over year, or 5.6% on a constant currency basis. U.S. net sales grew 3.0%, while international net sales increased 18.0% as reported and 16.2% on a constant currency basis.

GAAP net income was $151.6 million, down 25.3%, with GAAP diluted EPS of $1.10 versus $1.49, mainly due to a prior-year $110.5 million bargain purchase gain from the Nevro acquisition. Non-GAAP diluted EPS was $1.34, up 55.8%. Management cited approximately 200 basis points of adjusted gross margin expansion and record second quarter non-GAAP net income. The company reaffirmed full-year 2026 revenue guidance of $3.18–$3.22 billion and raised non-GAAP diluted EPS guidance to $4.95–$5.05 from $4.70–$4.80.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
-
Rhea-AI Summary

Globus Medical (NYSE:GMED) plans to release its financial results for the second quarter ended June 30, 2026 after market close on Thursday, August 6, 2026. The earnings release will be posted on the company’s investor website. A teleconference to discuss the results with the investment community will follow at 4:30 p.m. Eastern Time, accessible via live webcast and pre-registered telephone access, with an audio archive available afterward on the Investors page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
conferences earnings date
Rhea-AI Summary

Globus Medical (NYSE: GMED) reported Q1 2026 results: worldwide net sales $759.9M (+27.0%; +25.5% constant currency) and GAAP net income $124.3M. GAAP diluted EPS was $0.90 and non-GAAP diluted EPS was $1.12. The company reaffirmed 2026 revenue guide of $3.18B–$3.22B and raised non-GAAP EPS guidance to $4.70–$4.80. Management cited organic growth, Nevro acquisition contribution, margin expansion from operating leverage, and integration progress.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.37%
Tags

FAQ

What is the current stock price of Globus Medical (GMED)?

Globus Medical (GMED) last closed at $70.53.

What is the market cap of Globus Medical (GMED)?

The market cap of Globus Medical (GMED) is approximately $9.3B.